Literature DB >> 5158205

Inhibition of contact sensitivity in the mouse by topical application of corticosteroids.

D P Evans, M Hossack, D S Thomson.   

Abstract

1. Topical application of oxazolone to the ears of mice previously sensitized to this hapten resulted in a marked increase in ear weight 24 h later.2. Topical application of hydrocortisone, betamethasone 17-valerate, fluocinolone acetonide or triamcinolone acetonide inhibited this response in a dose dependent manner.3. The free alcohols of the three fluorinated compounds were only weakly active.4. Activity in this model was truly local. Oral administration of hydrocortisone or fluocinolone acetonide at doses comparable to those used topically failed to inhibit the ear swelling.5. Some steroids with poor anti-inflammatory properties had no significant effect.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5158205      PMCID: PMC1665907     

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  7 in total

1.  TOPICAL ACTIVITIES OF BETAMETHASONE ESTERS IN MAN.

Authors:  A W MCKENZIE; R M ATKINSON
Journal:  Arch Dermatol       Date:  1964-05

Review 2.  COMPARATIVE EFFICACY OF TOPICAL ANTI-INFLAMMATORY CORTICOSTEROIDS.

Authors:  C A SCHLAGEL
Journal:  J Pharm Sci       Date:  1965-03       Impact factor: 3.534

3.  Sodium retention and edema from percutaneous absorption of fludrocortisone acetate.

Authors:  T B FITZPATRICK; H C GRISWOLD; J H HICKS
Journal:  J Am Med Assoc       Date:  1955-07-30

4.  Contact and delayed hypersensitivity in the mouse. I. Active sensitization and passive transfer.

Authors:  G L Asherson; W Ptak
Journal:  Immunology       Date:  1968-09       Impact factor: 7.397

5.  Hypersensitivity in mice. I. Induction of contact sensitivity to oxazolone and inhibition by various chemical compounds.

Authors:  F M Dietrich; R Hess
Journal:  Int Arch Allergy Appl Immunol       Date:  1970

6.  Modified granuloma pouch procedure for the evaluation of topically applied anti-inflammatory steroids.

Authors:  G DiPasquale; C L Rassaert; E McDougall
Journal:  J Pharm Sci       Date:  1970-02       Impact factor: 3.534

7.  A bio-assay for the concomitant assessment of the antiphlogistic and thymolytic activities of topically applied corticoids.

Authors:  G Tonelli; L Thibault; I Ringler
Journal:  Endocrinology       Date:  1965-10       Impact factor: 4.736

  7 in total
  7 in total

1.  The pharmacological modulation of delayed type hypersensitivity (DTH) reactions to topical oxazolone in mouse skin.

Authors:  D Cavey; M Bouclier; G Burg; F Delamadeleine; C N Hensby
Journal:  Agents Actions       Date:  1990-01

2.  Mast cell interleukin-2 production contributes to suppression of chronic allergic dermatitis.

Authors:  Alon Y Hershko; Ryo Suzuki; Nicolas Charles; Damiana Alvarez-Errico; Jennifer L Sargent; Arian Laurence; Juan Rivera
Journal:  Immunity       Date:  2011-10-06       Impact factor: 31.745

3.  A novel contact hypersensitivity model for rank-ordering formulated corticosteroids.

Authors:  S C Bailey; F Asghar; P A Przekop; E S Kurtz
Journal:  Inflamm Res       Date:  1995-08       Impact factor: 4.575

4.  Role of the K(Ca)3.1 K+ channel in auricular lymph node CD4+ T-lymphocyte function of the delayed-type hypersensitivity model.

Authors:  Susumu Ohya; Erina Nakamura; Sayuri Horiba; Hiroaki Kito; Miki Matsui; Hisao Yamamura; Yuji Imaizumi
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

5.  Effect of selected immunoregulatory agents on low-grade contact sensitivity.

Authors:  D E Griswold; D T Walz
Journal:  Inflammation       Date:  1982-03       Impact factor: 4.092

6.  2,6-Di-tert-butyl-4-(2'-thenoyl)phenol(R-830): a novel nonsteroidal anti-inflammatory agent with antioxidant properties.

Authors:  G G Moore; K F Swingle
Journal:  Agents Actions       Date:  1982-12

7.  Animal models as tools to investigate antidiabetic and anti-inflammatory plants.

Authors:  Mohamed Eddouks; Debprasad Chattopadhyay; Naoufel Ali Zeggwagh
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-29       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.